XML 39 R25.htm IDEA: XBRL DOCUMENT
v3.23.2

Other Operating Income And Expenses | 6 Months Ended
--- | ---
Jun. 30, 2023
Analysis of income and expense [abstract] |
Other Operating Income and Expenses |
B.15. OTHER OPERATING INCOME AND EXPENSES
Other operating income amounted to €617 million in the first half of 2023 (versus €416 million in the first half of 2022), and Other operating expenses to €1,422 million (versus € 1,204 million in the first half of 2022). The main items included in Other operating income were: in the first half of 2023, (i) income from pharmaceutical partners of €160 million (versus €153 million in the first half of 2022), of which €102 million came from Regeneron (versus €133 million in the first half of 2022, see table below) and (ii) gains on disposals of assets and operations of €413 million, primarily on divestments of non strategic products (versus €288 million in the first half of 2022). Other operating expenses for the first half of 2023 included €1,423 million of expenses related to Regeneron (versus €1,201 million in the first half of 2022), as shown in the table below.
(€ million) | June 30, 2023 (6 months) | June 30, 2022 (6 months) | December 31, 2022 (12 months)
Income & expense related to profit/loss sharing under the Monoclonal Antibody Alliance | (1,449) |  | (979) |  | (2,325) |
Additional share of profit paid by Regeneron towards development costs | 291 |  | 97 |  | 434 |
Reimbursement to Regeneron of selling expenses incurred | (260) |  | (216) |  | (476) |
Total: Monoclonal Antibody Alliance | (1,418) |  | (1,098) |  | (2,367) |
Immuno-Oncology Alliance | — |  | 36 |  | 16 |
Other (mainly Zaltrap® and Libtayo®) | 97 |  | (6) |  | 1,120 |
Other operating income/(expenses), net related to Regeneron | (1,321) |  | (1,068) |  | (1,231) |
of which amount presented in “Other operating income” | 102 |  | 133 |  | 1,147 |

X
- References No definition available. + Details
Name: | ifrs-full_AnalysisOfIncomeAndExpenseAbstract
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The disclosure of other operating income or expense. [Refer: Other operating income (expense)] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2022-03-24 -Paragraph 10 -Subparagraph e -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_10_e&doctype=Standard -URIDate 2022-03-24 + Details
Name: | ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration